MedWatch

Coloplast has increased investment in company behind vapor therapy

In September, the medtech company Francis Medical has raised USD 55m for the further development of a potential water vapor ablation therapy for the treatment of prostate cancer. Coloplast – which was already one of its investors – has used the opportunity to invest even further in the US-based company.

Photo: Coloplast / PR

Coloplast's faith in a potential vapor ablation treatment for prostate cancer has grown stronger, having participated in a series B equity financing round of the US-based medtech company behind the treatment, the Danish company reports in its year-end report from 2020/2021.

Francis Medical has previously announced that the Series B financing round has brought the company USD 55m in funding. The Series B round was led by venture capital firm Solas Bioventures with previous investors participating, including Coloplast, which became an investor in the company with USD 4m in September 2020.

Read the whole article

Get 14 days free access.

No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs